Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HLA-A*11:01 (Monomer) protein (Biotin,KRAS G12A)

Origin: Human Host: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Catalog No. ABIN7454278
  • Target
    HLA-A*11:01
    Protein Type
    Recombinant
    Protein Characteristics
    Monomer
    Origin
    Human
    Source
    • 31
    • 6
    • 1
    HEK-293 Cells
    Purification tag / Conjugate
    Biotin,KRAS G12A
    Purpose
    Biotinylated Human HLA-A*11:01 & B2M & KRAS G12A (VVVGAAGVGK) Monomer Protein
    Sequence
    Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAAGVGK peptide
    Specificity
    Uni-Prot: AAV53343.1 (HLA-A*11:01), , P61769 (B2M), VVVGAAGVGK
    Characteristics
    Recombinant Biotinylated Human HLA-A*11:01 & B2M & KRAS G12A (VVVGAAGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide.
    Purity
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Sterility
    0.22 μm filtered
    Endotoxin Level
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
    Buffer
    Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
    Storage
    -20 °C,-80 °C
    Storage Comment
    -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Expiry Date
    12 months
  • Target
    HLA-A*11:01
    Background
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
    Molecular Weight
    50.30 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.
You are here:
Support